News
News-Medical.Net on MSN12h
Oncolytic viruses integrated with immunotherapy for next-generation cancer treatment
The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients.
Listed Funds Trust - Overlay Shares Small Cap Equity ETF (OVS) Declares $0.26 Dividend July 05, 2023 — 12:35 am EDT Written by George Maybach for Fintel -> ...
Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment
The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new ...
Quarterly Performance Highlights OVS reported Q1 2025 net sales of €354.4 million, representing a 0.6% increase compared to the same period in 2024.
Despite a weaker-than-expected start, OVS SpA (FRA:0OV1) leverages strategic acquisitions and favorable market conditions to drive future growth.
TipRanks on MSN12d
OVS S.p.A. Executes Share Buyback Program
OVS S.p.A. ( ($IT:OVS) ) has provided an update. OVS S.p.A. announced the purchase of 20,791 of its own shares on Euronext Milan, representing ...
OVS S.p.A. quarterly income statement. View OVS.IT financial statements in full, including balance sheets and ratios.
OVS reported Q1 2025 net sales of €354.4 million, representing a 0.6% increase compared to the same period in 2024. This growth was achieved despite what the company described as "a market still held ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback